Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects [clinicaltrials:NCT02079480]

Bio2RDF identifier

NCT02079480

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT02079480

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT02079480

anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]

130

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT02079480 arm group 379c2c7e2cf67fabd847d48182d8b296 [clinicaltrials_resource:NCT02079480/arm-group/379c2c7e2cf67fabd847d48182d8b296]

NCT02079480 arm group 3bb02b3617385dbafb6b7ebc6014fc2c [clinicaltrials_resource:NCT02079480/arm-group/3bb02b3617385dbafb6b7ebc6014fc2c]

NCT02079480 arm group 51a8c63d0788de0c0113868cb1a7568f [clinicaltrials_resource:NCT02079480/arm-group/51a8c63d0788de0c0113868cb1a7568f]

NCT02079480 arm group 572df81149f49e8b0c3c459a6eb0f2db [clinicaltrials_resource:NCT02079480/arm-group/572df81149f49e8b0c3c459a6eb0f2db]

NCT02079480 arm group 64543a247fd09fba8e3134415601041b [clinicaltrials_resource:NCT02079480/arm-group/64543a247fd09fba8e3134415601041b]

NCT02079480 arm group 7657cafc4f26d598a302e54e8e672fe6 [clinicaltrials_resource:NCT02079480/arm-group/7657cafc4f26d598a302e54e8e672fe6]

NCT02079480 arm group ab37847d4a3a0dae957f092eba8da01b [clinicaltrials_resource:NCT02079480/arm-group/ab37847d4a3a0dae957f092eba8da01b]

NCT02079480 arm group c161919f084f9e21ad5293d7c425af23 [clinicaltrials_resource:NCT02079480/arm-group/c161919f084f9e21ad5293d7c425af23]

NCT02079480 arm group e16b0c9d30863cff658c733583a41988 [clinicaltrials_resource:NCT02079480/arm-group/e16b0c9d30863cff658c733583a41988]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:d942c8692d257084abf3ac87279faff6

brief summary [clinicaltrials_vocabulary:brief-summary]

The purpose of this stu ...... S-986090 in healthy subjects.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Safety and tolerability of single dose measured by incidence, potential significance and clinical importance of AEs, as determined by medical review of AE reports, vital sign measurements, ECGs and results of physical examination and laboratory tests Up to Day 85 after single dose of BMS-986090 [clinicaltrials_resource:66dc0008935fa9cb6dd0a6aca00b8903]

Safety and tolerability of single dose measured by incidence, potential significance and clinical importance of AEs, as determined by medical review of AE reports, vital sign measurements, ECGs and results of physical examination and laboratory tests Up to Day 85 after single dose of BMS-986090 [clinicaltrials_resource:d08d4f96a486c21a41d83739b1789319]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Safety and tolerability of single dose measured by incidence, potential significance and clinical importance of AEs, as determined by medical review of AE reports, vital sign measurements, ECGs and results of physical examination and laboratory tests Up to Day 85 after single dose of BMS-986090 [clinicaltrials_resource:024cbd2af0861dc7f284402fa6705b70]

Safety and tolerability of single dose measured by incidence, potential significance and clinical importance of AEs, as determined by medical review of AE reports, vital sign measurements, ECGs and results of physical examination and laboratory tests Up to Day 85 after single dose of BMS-986090 [clinicaltrials_resource:0b85986bb623369ca438770b69e4774f]

Safety and tolerability of single dose measured by incidence, potential significance and clinical importance of AEs, as determined by medical review of AE reports, vital sign measurements, ECGs and results of physical examination and laboratory tests Up to Day 85 after single dose of BMS-986090 [clinicaltrials_resource:0e85cbe13a5e2f7bad5dca800472c228]

Safety and tolerability of single dose measured by incidence, potential significance and clinical importance of AEs, as determined by medical review of AE reports, vital sign measurements, ECGs and results of physical examination and laboratory tests Up to Day 85 after single dose of BMS-986090 [clinicaltrials_resource:2c973e907815624a6cebda026e0ba6d5]

Safety and tolerability of single dose measured by incidence, potential significance and clinical importance of AEs, as determined by medical review of AE reports, vital sign measurements, ECGs and results of physical examination and laboratory tests Up to Day 85 after single dose of BMS-986090 [clinicaltrials_resource:2ca18c4e4ae3239ea4a481880bd46ce9]

Safety and tolerability of single dose measured by incidence, potential significance and clinical importance of AEs, as determined by medical review of AE reports, vital sign measurements, ECGs and results of physical examination and laboratory tests Up to Day 85 after single dose of BMS-986090 [clinicaltrials_resource:2cfe2cf19af17fd6ce248b40f35f62c4]

Safety and tolerability of single dose measured by incidence, potential significance and clinical importance of AEs, as determined by medical review of AE reports, vital sign measurements, ECGs and results of physical examination and laboratory tests Up to Day 85 after single dose of BMS-986090 [clinicaltrials_resource:346f13279582fcd1f56fbc6c791a417c]

Safety and tolerability of single dose measured by incidence, potential significance and clinical importance of AEs, as determined by medical review of AE reports, vital sign measurements, ECGs and results of physical examination and laboratory tests Up to Day 85 after single dose of BMS-986090 [clinicaltrials_resource:34c361c4efc236b7946a9687dbcbcc77]

Safety and tolerability of single dose measured by incidence, potential significance and clinical importance of AEs, as determined by medical review of AE reports, vital sign measurements, ECGs and results of physical examination and laboratory tests Up to Day 85 after single dose of BMS-986090 [clinicaltrials_resource:4a7c2b4b0f057b86fdae82ef372a33af]

Safety and tolerability of single dose measured by incidence, potential significance and clinical importance of AEs, as determined by medical review of AE reports, vital sign measurements, ECGs and results of physical examination and laboratory tests Up to Day 85 after single dose of BMS-986090 [clinicaltrials_resource:5d093f6371843343fb030bf4db69b6c0]

completion date [clinicaltrials_vocabulary:completion-date]

2015-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

condition [clinicaltrials_vocabulary:condition]

Healthy Adult Volunteers [clinicaltrials_resource:da52f3d9f697b392dc5cc697333285a9]

country [clinicaltrials_vocabulary:country]

United States [clinicaltrials_resource:f253efe302d32ab264a76e0ce65be769]

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT02079480 [clinicaltrials_resource:67162ebf0422d68c55db0711a047c885]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2014-03-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

BMS-986090 [clinicaltrials_resource:852b83faa8ce08dea6e74030452fbee6]

Keyhole limpet hemocyanin [clinicaltrials_resource:938e9e245035ffdb89908d2a55472488]

Placebo matching with BMS-986090 [clinicaltrials_resource:fadec83b4544eeeb523b0b0ccad6dfcf]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Keyhole-limpet hemocyanin [clinicaltrials_resource:d5ef4ca1260d86c18818dd4693482af2]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

No

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-07-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

nct id [clinicaltrials_vocabulary:nct-id]

NCT02079480

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

9

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

Double-Blinded, Randomized, Pl ...... BMS-986090 in Healthy Subjects

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

IM142-003

http://www.w3.org/2001/XMLSchema#string

overall contact [clinicaltrials_vocabulary:overall-contact]

Bristol-Myers Squibb [clinicaltrials_resource:3198a154b3c6ab71c470cee213664836]

overall contact backup [clinicaltrials_vocabulary:overall-contact-backup]

Bristol-Myers Squibb [clinicaltrials_resource:8dd8033e871f3c82c52377f2b0914757]

overall official [clinicaltrials_vocabulary:overall-official]

Bristol-Myers Squibb [clinicaltrials_resource:d3a813b7ce44062a0bf05c46ffe9add7]

overall status [clinicaltrials_vocabulary:overall-status]

Recruiting [clinicaltrials_resource:5231dee7156b84b0d1854de1a18dd169]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:965595316c5ae1a4521a298d475eb908]

phase [clinicaltrials_vocabulary:phase]

Phase 1 [clinicaltrials_resource:ee4650e51426c7487977eeea8e7e6850]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2015-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

source [clinicaltrials_vocabulary:source]

Bristol-Myers Squibb [clinicaltrials_resource:d4c40cb9f02fd866ab671f3ce45dfa72]

start date [clinicaltrials_vocabulary:start-date]

2014-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT02079480 study design [clinicaltrials_resource:c192526e6f9b4f0fb0f1d00b5da19ebd]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT02079480

verification date [clinicaltrials_vocabulary:verification-date]

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT02079480

http://www.w3.org/2001/XMLSchema#string

title

Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Study to Evaluate the Safety, ...... s [clinicaltrials:NCT02079480]

@en